You are here: News > Amryt Pharma announces positive top line results from pivotal phase 3 “EASE” trial of wound healing gel in Epidermolysis Bullosa

Amryt Pharma announces positive top line results from pivotal phase 3 “EASE” trial of wound healing gel in Epidermolysis Bullosa

We are excited to share the positive results of a global trial by Amyrt Pharma of a topical therapeutic gel treatment which could potentially increase the speed of wound healing for people affected by the devastating skin condition Epidermolysis Bullosa (EB).

"This is an exciting development by Amryt Pharma who are announcing positive trial results for potentially the first approved topical therapeutic gel treatment for EB. It is a very solid step forward in bringing new treatments into the clinic for this devastating disease." commented Caroline Collins, Director of Research for DEBRA UK.

Dr Joe Wiley, CEO of Amryt Pharma, commented "We are proud to present these positive and encouraging results, demonstrating that FILSUVEZ® could make an important difference to the lives of patients. We would like to extend our gratitude to all of the patients, their families, carers and physicians for their participation in the EASE trial and we look forward to working with regulatory authorities to make FILSUVEZ® available as the first approved therapeutic treatment for EB patients. All of the team at Amryt are very excited by today’s news and the impact this may have in our efforts to help patients with this very distressing condition."

Read the key facts about the trial, the results and what happens next below.

Please check back for the Q&A by DEBRA International.

To find out whether this treatment is appropriate for you, please speak to your healthcare team. To find out about the research that DEBRA is investing in to #FightEB, click here.

Make a difference

Make a difference

Please help us fund vital healthcare such as specialist EB nurses as well as research, care and life-changing support. 

Donate Today